CA Patent

CA2794798C — Treatment of gout

Assigned to Ardea Biociences Inc · Expires 2017-05-30 · 9y expired

What this patent protects

The invention relates to sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate. Additionally, the invention relates to pharmaceutical compositions and uses of these compositions for the treatment of a variety of diseases and disorders.

USPTO Abstract

The invention relates to sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate. Additionally, the invention relates to pharmaceutical compositions and uses of these compositions for the treatment of a variety of diseases and disorders.

Drugs covered by this patent

Patent Metadata

Patent number
CA2794798C
Jurisdiction
CA
Classification
—
Expires
2017-05-30
Drug substance claim
No
Drug product claim
No
Assignee
Ardea Biociences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.